Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Pediatric Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1505257

Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with long-term response: Report of a rare case

Provisionally accepted
Thomas COCHIN Thomas COCHIN 1*Sabine NOAL Sabine NOAL 1Dinu Stefan Dinu Stefan 1Damien Bodet Damien Bodet 2Jérémie Rouger Jérémie Rouger 2Marine Dorbeau Marine Dorbeau 2Zoé NEVIERE Zoé NEVIERE 1*
  • 1 Centre François Baclesse, Caen, France
  • 2 Department of Pediatric Oncology and Hematology, University Hospital of Caen, Caen, Lower Normandy, France

The final, formatted version of the article will be published soon.

    Inflammatory myofibroblastic tumors (IMTs) are known to be associated with rearrangements of the anaplastic lymphoma kinase (ALK) gene. The treatment of this type of tumor includes systemic therapies such as chemotherapies or anti-inflammatories; in recent years, targeted anti-ALK therapies have emerged and became the standard of care in ALK rearranged patients.We aimed to present a rare case of musculoskeletal IMT with ALK rearrangement, characterized by metastatic evolution and enhanced responses to sequential treatment with all ALK-TKI.We have outlined a potential treatment pathway involving sequential ALK-TKI targeted therapies and successive local interventions to control the cancer.

    Keywords: inflammatory myofibroblastic tumor, CRIZOTIB, sequential treatment ALK-TKI, pediatric, ALK inhibitor

    Received: 02 Oct 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 COCHIN, NOAL, Stefan, Bodet, Rouger, Dorbeau and NEVIERE. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Thomas COCHIN, Centre François Baclesse, Caen, France
    Zoé NEVIERE, Centre François Baclesse, Caen, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.